These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 21541491)
1. Intrasplenic vaccination against experimental melanoma. Shrayer D; Park C; Kouttab N; Bogaars H; McInnis R; Paul S; Maizel A; Hearing V; Wanebo H Int J Oncol; 1996 Jul; 9(1):123-9. PubMed ID: 21541491 [TBL] [Abstract][Full Text] [Related]
2. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
4. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Shrayer D; Kouttab N; Maizel A; Wanebo H; Hearing VJ; Gersten DM Int J Cancer; 1993 Feb; 53(4):696-702. PubMed ID: 8436442 [TBL] [Abstract][Full Text] [Related]
5. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma. Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154 [TBL] [Abstract][Full Text] [Related]
6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
7. A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134 [TBL] [Abstract][Full Text] [Related]
8. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Donskov F; Basse PH; Hokland M Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263 [TBL] [Abstract][Full Text] [Related]
9. [Effects of excreted/secreted antigens of Toxoplasma gondii on CD4+ CD25+ Foxp3+ T cells and NK cells of melanoma-bearing mice]. Jiao YM; Zhang L; Ge YY; Liang YJ; Yong W Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2011 Jun; 23(3):301-6. PubMed ID: 22164498 [TBL] [Abstract][Full Text] [Related]
10. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination]. Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746 [TBL] [Abstract][Full Text] [Related]
11. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
12. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma. Shrayer D; Koness J; Maizel A; Wanebo H Melanoma Res; 1992 May; 2(1):47-56. PubMed ID: 1643424 [TBL] [Abstract][Full Text] [Related]
13. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Kalland T Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041 [TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity between murine melanoma antigen B700 and a human melanoma-associated antigen (M-66) recognized by autologous antibody: evidence suggesting shared epitopes. Toporowicz A; Gersten DM; Hearing VJ; Brown WE; Vlock DR Biochim Biophys Acta; 1993 Aug; 1182(1):51-6. PubMed ID: 7688577 [TBL] [Abstract][Full Text] [Related]
15. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of polyvalent and monovalent vaccines coupled with interleukin-2 in a metastatic melanoma model. Shrayer D; Koness J; Kouttab N; Bogaars H; Hearing V; Maizel A; Wanebo H Int J Oncol; 1994 May; 4(5):1121-7. PubMed ID: 21567029 [TBL] [Abstract][Full Text] [Related]
17. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Björkdahl O; Dohlsten M; Sjögren HO Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695 [TBL] [Abstract][Full Text] [Related]
18. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury]. Tan XH; Wan YH Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524 [TBL] [Abstract][Full Text] [Related]
19. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related]
20. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]